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The publication of Australian fetal alcohol spectrum disorder (FASD) diagnostic guidelines marks an important step
forward in Australia’s efforts to prevent FASD. But do we need yet another set of FASD guidelines? At the 5th
International FASD Conference, the ever growing number of FASD diagnostic guidelines was identified as a core
area of concern by leaders in FASD worldwide. All agreed we need to strive to adopt a single set of guidelines. It is
essential that FASD diagnosis advance to incorporate new knowledge and technology. But to date, the field of
FASD has seen multiple sets of guidelines published that do not address the important question-How is the
performance of these new guidelines superior to the performance of existing guidelines to warrant/justify their
introduction into the medical literature?
The Australian guidelines include FAS, PFAS and Neurodevelopmental Disorder-Alcohol Exposed (ND-AE). This latter
group includes individuals with severe CNS abnormalities without the physical features of FAS. This is the group the
4-Digit-Code calls Static-Encephalopathy-Alcohol-Exposed (SE-AE). The criteria for FAS, PFAS, and ND-AE (or what
the 4-Digit-Code calls SE-AE) are identical between the Australian and 4-Digit-Code guidelines with the exception
of one very small, but very consequential difference in facial criteria for PFAS. The 4-Digit-Code requires a Rank 3
FAS facial phenotype for PFAS (J Popul Ther Clin Pharmacol 20(3):e416–e467, 2013); the Australian guidelines relax
the criteria to include the Rank 2 FAS facial phenotype. This relaxation of the criteria renders the facial phenotype
NOT specific to prenatal alcohol exposure as confirmed in published empirical studies. If the facial phenotype is not
specific to (caused only by) prenatal alcohol exposure one can no longer validly call the outcome PFAS. When one
makes a diagnosis of FAS (full or partial), one is stating explicitly that the individual has a syndrome caused by
prenatal alcohol exposure. One is also stating explicitly that the biological mother drank alcohol during pregnancy
and, as a result, harmed her child. These are bold conclusions to draw and are not without medical, ethical, and
even legal consequences. So the question remains-Why go against the published empirical evidence and relax the
PFAS facial criteria into the normal range?
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order (FASD) diagnostic guidelines [1] marks an import-
ant step forward in Australia’s efforts to prevent FASD.
Accurate identification of the full spectrum of outcome
caused by prenatal alcohol exposure is central to FASD
screening, diagnosis, intervention, surveillance, and
ultimately prevention [2,3]. But do we need yet another
set of FASD guidelines?
FASD diagnostic guidelines have evolved over time
since the term FAS was first coined in 1973 [4]. EarlyCorrespondence: astley@uw.edu
FAS Diagnostic & Prevention Network, Center on Human Development and
Disability, University of Washington, Box 357920, Seattle, WA 98195-7920, USA
© 2014 Astley; licensee BioMed Central Ltd. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.guidelines were gestalt (purposely broad and conceptual)
in nature and administered primarily by geneticists/
dysmorphologists. The 1996 Institute of Medicine FASD
guidelines [5] would be the last in this line of gestalt
approaches to diagnosis. In 1997, the FASD 4-Digit-
Diagnostic-Code was introduced to overcome the limita-
tions (inaccuracies) of the gestalt method of diagnosis [6-8].
The 4-Digit-Code introduced an interdisciplinary approach
guided by rigorously and empirically case-defined criteria.
When the 4-Digit-Code was introduced into the medical
literature, it was presented in the form of an empirical
study demonstrating its superior performance to the gestalt
approach it proposed to replace [7]. Over the next 17 years,is is an Open Access article distributed under the terms of the Creative
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(validated [2,9]) through MRI studies [10], population-
based screening/surveillance studies [11-14], and pa-
tient follow-up surveys [15]. Between 2004 and 2013,
five additional FASD diagnostic guidelines will be intro-
duced into the literature [16-19]. All proposed an inter-
disciplinary approach using defined criteria. Most were
established through a consensus process, but none had
performance assessed (validated) prior to or even after
publication. Most present with criteria that are margin-
ally different from the 4-Digit-Code, but none provide
empirical evidence demonstrating their superior per-
formance relative to existing guidelines. It is essential
that FASD diagnosis advance to incorporate new know-
ledge and technology. But to date, the field of FASD has
seen multiple sets of guidelines published that do not
address the important question-How is the performance
of these new guidelines superior to the performance of
existing guidelines to warrant/justify their introduction
into the medical literature [2]? At the 5th International
FASD Conference in 2013, the ever growing number of
FASD diagnostic guidelines was identified as a core area
of concern by leaders in FASD worldwide. All agreed we
need to strive to adopt a single set of guidelines.
The most recent guidelines introduced into the literature
are the Australian guidelines [1]. More accurately, they are
consensus recommendations providing a foundation for de-
velopment of Australian FASD diagnostic guidelines. The
Australian guidelines adapted elements of the 4-Digit-Code
and Canadian Guidelines. Let’s take a closer look.
The Australian guidelines include FAS, PFAS and
Neurodevelopmental Disorder-Alcohol Exposed (ND-AE).
This latter group includes individuals with severe CNS
abnormalities without the physical features of FAS. This is
the group the 4-Digit-Code calls Static-Encephalopathy-
Alcohol-Exposed (SE-AE). The Australian guidelines chose
not to use the term Alcohol-Related-Neurodevelopmental-
Disorder (following the 4-Digit Code and DSM-5 [20]
conventions) due to the implication of causality between
exposure and outcome that cannot be confirmed. The cri-
teria for FAS, PFAS, and ND-AE (or what the 4-Digit-Code
calls SE-AE) are identical between the Australian and
4-Digit-Code guidelines with the exception of one very
small, but very consequential difference in facial criteria for
PFAS. The 4-Digit-Code requires a Rank 3 FAS facial
phenotype (“2.5” of the 3 facial features must be present)
for PFAS; the Australian guidelines relax the criteria to in-
clude the Rank 2 FAS facial phenotype (2 of the 3 facial fea-
tures). This relaxation of the criteria renders the facial
phenotype NOT specific to prenatal alcohol exposure as
confirmed in published empirical studies [2,3,21,22]. In
one of those studies 25% of a group of high-functioning
(mean IQ 120) children with confirmed absence of pre-
natal alcohol exposure presented with 2 of the 3features. This study clearly demonstrated that the PFAS
facial phenotype proposed in the Australian guidelines
is not observed exclusively among children damaged
by prenatal alcohol exposure. If the facial phenotype is
not specific to (caused only by) prenatal alcohol exposure
(and we already know the growth and CNS abnormalities
are not caused only by prenatal alcohol exposure) one can
no longer validly call the outcome PFAS. This problem is
not resolved by requiring a confirmed prenatal alcohol ex-
posure. The problem lies in the name (PFAS) given to the
condition. When one makes a diagnosis of FAS (full or
partial), one is stating explicitly that the individual has a
syndrome caused by prenatal alcohol exposure. One is
also stating explicitly that the biological mother drank al-
cohol during pregnancy and, as a result, harmed her child.
These are bold conclusions to draw and are not without
medical, ethical, and even legal consequences. If the
growth, face and CNS criteria for PFAS are not specific to
prenatal alcohol exposure, a clinical team is in no position
to claim the child has a condition caused by their mother‶s
alcohol use. A second problem arises with the relaxation of
the facial features for PFAS into the normal range (re-
quiring only 2 of the 3 features). If the facial criteria are
relaxed, the Australian PFAS group is no longer clinic-
ally distinct from the Australian ND-AE group [2,3].
Note the only feature that distinguishes the Australian
PFAS group from their ND-AE group is the facial cri-
teria. But if the facial criteria for PFAS are relaxed into
the normal range, the facial criteria are no longer clinic-
ally distinct from the facial criteria for ND-AE. If there
is no clinically meaningful distinction between PFAS
and ND-AE, what is the justification for creating two sep-
arate diagnostic subgroups? So the question remains-
Why go against the published empirical evidence and
relax the PFAS facial criteria into the normal range?
The Australian guidelines report the UW 4-Digit-Code
could also be derived if desired“. Unfortunately, the only
issue preventing clinicians from deriving a 4-Digit-Code
that would be in complete compliance with the Australian
guidelines is the relaxation of the PFAS facial criteria from
a Rank 3 to a Rank 2. If the Australian guidelines required
a Rank 3 face for PFAS, it would not only gain the specifi-
city required to validate the use of the term PFAS, but the
4-Digit-Codes would derive 4-Digit clinical categories
(FAS, PFAS, SE-AE) that match the Australian clinical
categories (FAS, PFAS, ND-AE). If the 4-Digit-Code
said it was FAS, so would the Australian guidelines. If the
4-Digit-Code said it was PFAS, so would the Australian
guidelines. And if the 4-Digit-Code said it was SE-AE,
so would the Australian guidelines (but the Australian
guidelines would simply give it a different label (ND-AE)).
Individuals who present with moderate CNS dysfunction
(what the 4-Digit-Code calls Neurobehavioral-Disorder-
Alcohol-Exposed) would receive 4-Digit-Codes documenting
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lines would not receive a label. This would seem a reason-
able interim solution as Australians further assess how
to handle this moderate end of the FASD spectrum. The
authors report “Although there is an extensive evidence
base confirming prenatal alcohol exposure causes the full
range of outcomes from moderate to severe CNS dysfunction
and a growing evidence base documenting significant CNS
structural abnormalities among alcohol-exposed individuals
with moderate dysfunction; panel members identified
the need for additional evidence to more fully evaluate
the validity of diagnosis based on moderate CNS dysfunction”
Rendering a 4-Digit-Code would allow one to quickly
apply a label retroactively in the event Australia elects
to recognize (e.g., label) this moderate end of the FASD
spectrum in the future.
Response
Rochelle E Watkins, Elizabeth J Elliott, Janet M Payne,
Colleen M O’Leary, Jane Halliday, Jane Latimer, Amanda
Wilkins, Raewyn C Mutch, James P Fitzpatrick, Heather
M Jones, Lorian Hayes, Heather D’Antoine, Sue Miers,
Elizabeth Russell, Lucinda Burns, Anne McKenzie,
Maureen Carter, Carol Bower.
We have recently published recommendations for the
diagnosis of fetal alcohol spectrum disorders (FASD) in
Australia. These recommendations seek to address the
known issue of underdiagnosis through supporting
improved awareness of FASD and increased national
capacity to respond to, and ultimately prevent, these
disorders. We used an adaption approach to guideline
development in recognition of existing diagnostic
guidelines. Recommended national standard diagnostic
criteria for Australia are based on the University of
Washington (UW) 4-Digit Diagnostic Code and Canadian
guidelines for FASD diagnosis. Our conclusions emphasise
the importance of evaluation to improve the evidence-base
for policy and practice.
In her commentary on our recommendations, Astley
has raised important questions about the publication of
this work, including whether we need ‘yet another guide-
line’, and expressed concern about the recommended cri-
teria for the diagnosis of partial fetal alcohol syndrome
(PFAS). Guideline development is a recognised and widely
used mechanism to influence clinical practice. The lack of
guidelines for diagnosis in Australia has been identified as
one of the factors contributing to the underdiagnosis of
FASD. We sought to establish the basis for a standard
national approach to diagnosis in Australia through the
adoption or adaption of existing guidelines.
Existing diagnostic guidelines lack agreement on all
aspects of diagnosis, and the recommended diagnostic
criteria for PFAS remain subject to debate. Although our
recommended diagnostic criteria for PFAS in Australiabased on the presence of 2 characteristic facial features
differ from the UW guidelines, they lie within the
range of criteria recommended by other guidelines. We
sought peer review and publication of our findings to
provide transparency and promote awareness of our
work nationally and internationally. We support inter-
national collaboration to develop a common approach to
diagnosis, and believe that this process will strengthen the
evidence base for action globally.
Background
North America leads the world in the production of
guidelines for the diagnosis of fetal alcohol spectrum
disorder (FASD), and these provide a rich resource for
those seeking to address and prevent the harm caused by
prenatal exposure in other contexts. We recently published
Australian recommendations for FASD screening and
diagnosis [1] with the aim of supporting clinical decision-
making to improve the identification, management and
prevention of these disorders based on a standard national
approach. In her commentary on our recommendations,
Astley has raised some important questions about the
need for these guidelines, the publication of this work and
the recommended criteria for the diagnosis of partial fetal
alcohol syndrome (PFAS).
National focus
The development of clinical practice guidelines has been
identified as a critical activity at the national level to
facilitate the delivery of effective health services [23].
The majority of published guidelines for the diagnosis
of FASD were commissioned by government health
agencies and motivated by concern about the impact of
prenatal alcohol exposure at a national level. It is unlikely
to be coincidental that North America has both published
the greatest number of guidelines for diagnosis and gained
recognition as leading the world in many aspects of FASD
practice and research.
Guidelines are developed with the aim to influence
practice. They need to be locally appropriate and integrated
with strategies to facilitate their implementation. High
quality guidelines developed at the international level
can facilitate the development of locally appropriate
guidelines for specific practice settings and, increasingly,
local health providers are developing methods to integrate
evidence in their own settings [24]. The need to improve
service delivery and support health professionals’ capacity
to diagnose FASD in Australia [25,26] underpinned the
Australian Government’s call for development of a diag-
nostic instrument for Australia. The absence of guide-
lines for FASD diagnosis in Australia has been linked to
underdiagnosis [27] and inaccurate FASD prevalence es-
timates [28]. The lack of a national standard approach
undermines the effectiveness of interventions to educate
Astley BMC Pediatrics 2014, 14:85 Page 4 of 6
http://www.biomedcentral.com/1471-2431/14/85health professionals, increase diagnostic and manage-
ment capacity, and conduct surveillance and evaluation.
Adoption or adaption
Through the development of national recommendations
for FASD screening and diagnosis we aimed to improve
awareness of FASD and strengthen national capacity to
identify, address and prevent the harms associated with
alcohol consumption in pregnancy. Four key factors
framed our approach: i) that there are no international
consensus criteria for diagnosis; ii) that there is variation
in diagnostic practices internationally [29]; iii) that the
most recent guidelines were published in 2005, and none
with a published formal review; and iv) that there was
little evidence to support the natural emergence of any
standard national approach to diagnosis in Australia.
A range of existing guidelines have been used for diag-
nosis in Australia. The Institute of Medicine criteria [5]
were used in the first national surveillance study in 2001
[30], the Canadian guidelines [17] were used in the first
national prevalence study in 2009 [31], and the University
of Washington (UW) 4-Digit Diagnostic Code [8] has
been proposed for national use by authors examining the
issues of diagnostic capacity and surveillance [27,28].
We used an adaption approach to development [32] in
recognition of existing guidelines for diagnosis, and our
work followed the accepted process of identifying whether
existing guidelines would be adopted or adapted for local
use [33] within a recognised research framework [34,35].
We found no clear support for the adoption of any single
existing guideline [1,26]. Our recommendations have been
developed to provide the foundation for a coordinated na-
tional approach to service provision, and are based on the
cornerstone contributions of existing diagnostic guidelines
that have helped to advance practice globally.
Process and judgement
There are considerable challenges in producing evidence-
based guidelines for FASD screening and diagnosis, and
disagreement between guidelines can arise for various rea-
sons, not all of which imply that different recommenda-
tions are invalid [36]. We developed recommendations for
Australia based on the deliberations of a range of stake-
holders within a consensus-based approach. As is often
the case in guideline development, there was a recognised
need to move beyond the limited research evidence [37],
and rarely ‘an abundance of evidence available that
leads directly to an indisputable recommendation’ [38]
p. 35. Recommendation development is a largely qualitative
process with the need to consider multiple factors and con-
siderable potential to encounter differences in judgement
for a number of reasons, including perceptions about rele-
vance, feasibility, risks and benefits. Panel members noted
the need for additional evidence to evaluate differences inrecommendations between existing guidelines, as well as
the recommendations developed for Australia [1].
In the specific case of differences between the UW and
Australian recommendations with respect to the facial
features required for a diagnosis of PFAS, the panel recog-
nised that the criteria for the diagnosis of PFAS remain
subject to debate [39,40]. Diagnosis of disorders within
the FASD spectrum is consistently challenged by an
insufficient understanding of factors which contribute to
individual susceptibility and phenotypic variability, and
research highlights both the clinical significance of facial
abnormalities [41,42] and the potential for variation in
facial dysmorphology [43,44]. We support the need for
further research to examine the validity of recommended
diagnostic criteria for PFAS and facilitate international
consensus in this area, and believe it would be premature
to conclude that the diagnostic category of PFAS based on
the presence of 2 facial features is invalid at this time.
Recommended facial criteria for the diagnosis of PFAS
in Australia are consistent with existing guidelines [17,18],
and differences in categorisation between the UW and
other guidelines do not result in substantial differences
in outcomes such as a diagnosis on the spectrum where
one would otherwise have not been made. With reference
to the potential harm caused by a diagnosis of PFAS using
the recommended Australian criteria, we do not claim
causation in the case of PFAS when diagnosed based
on the presence of 2 characteristic facial features. The
use of a non-causal assumption could be considered
more conservative than assuming causation where specifi-
city is known to be less than 100%. Contrary to Astley’s
comment, sufficient detail is recorded during the rec-
ommended assessment process to enable derivation of
the 4-Digit Diagnostic Code despite differences between
the diagnostic categories recommended in Australia
and the UW guidelines. Further evaluation is critical to
validating diagnostic criteria, and ensuring that the diag-
nostic categories used are based on meaningful distinctions
across the spectrum.
We believe that our work provides a credible basis for
advancing practice in Australia and, consistent with
the purposes of the scientific literature and the need
for transparency in recommendation development, we
sought peer review and publication of a research paper
which documents the methods used to develop these
recommendations. If, through seeking peer review and
publication to promote national and international aware-
ness of our goals and progress, this process highlights
broader issues that confront the development of FASD
guidelines internationally, then we have achieved more
than we had hoped.Competing interests
The author declares that she has no competing interests.
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